Osel

Executive Summary

Osel Inc. is a clinical-stage biopharmaceutical company pioneering Live Biotherapeutic Products (LBPs) to treat diseases by modulating the human microbiome. With a focus on women's health and oncology, its lead candidate MO-03 is poised to enter a pivotal Phase 3 trial for renal cell carcinoma (RCC), a significant milestone that could validate microbiome-based therapies in oncology. The company's proprietary platform enables the development of targeted bacterial consortia, and its pipeline includes candidates for preterm birth and bacterial vaginosis. Founded in 1998 and based in Mountain View, California, Osel is positioned to be a first-mover in the LBP space. The upcoming Phase 3 initiation for MO-03, potential data from ongoing studies, and possible strategic partnerships are key catalysts that underscore the company's clinical and regulatory momentum.

Upcoming Catalysts (preview)

• H2 2026Initiation of Pivotal Phase 3 Trial for MO-03 in Renal Cell Carcinoma75% success
• H1 2027Phase 2 Data Readout for Women's Health Candidate (Bacterial Vaginosis or Preterm Birth)60% success
• Q4 2026Announcement of Strategic Partnership or Licensing Deal for LBP Platform50% success